Demand in the Covid-19 tests market has dramatically declined since its peak in Q4 2021. Additionally, while there was a spike in purchases of Covid-19 tests during December 2020 – January 2021 and December 2021 – January 2022, that spike did not occur during December 2022 – January 2023. However, despite the fact that there have been decreases in the number of confirmed Covid-19 cases, there is still a steady demand for testing. To put this in perspective, current GlobalData estimates show that the Covid-19 tests market revenue for January 2023 is equivalent to 70% of the market revenue for December 2020, when testing was in dire need.
While Covid-19 is no longer a pressing concern for many people due to vaccine rollouts and health and safety policies, a percentage of the population still takes these tests to monitor for potential infections, when in preparation for international travel, or due to working at companies that require employees to provide a negative test in order to return to work. This has resulted in a more resilient market than previously expected.
Go deeper with GlobalData
Cepheid continues to be the clear market leader in Covid-19 testing and has retained this status for the last 18 months, while other competitors such as F Hoffmann-La Roche and Abbott have gradually decreased their market share.
Cepheid’s rollout of products such as Xpert Xpress CoV-2/Flu/RSV plus and Xpert Xpress CoV-2plus has allowed the company to capitalise on concerns about multiple variants of Covid-19, which has been a key mechanism to its success. This product not only has enhanced gene coverage but also tests for multiple influenza-like illnesses. The adaptability of these rapid testing devices will likely benefit them not only in Covid-19 tests but in the overall in vitro diagnostics (IVD) market.
Since Covid-19 remains in an endemic status and the behaviour of the virus makes long-term immunity difficult, the need for testing is expected to be continuous, but not to remain at the same levels shown at the height of the Covid-19 pandemic. Companies, such as Cepheid, that can adapt their products to address the changing nature of the virus and future variants will make notable gains in this market.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
F. Hoffmann-La Roche Ltd
Cepheid Inc
Abbott GmbH & Co KG